Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Dynacure SAS
While COVID-19 shocked global financial markets and is expected to impact biopharma fundraising, investment in drug developers continues, including through two new venture capital funds totaling nearly $2bn. Also, Coherus issues debt to fund deals and MOMA launches with $86m in VC cash.
France’s fledgling biotech Dynacure has pulled together a series C funding round to support its ongoing Phase I/II study of an antisense molecule for an ultrarare myopathy.
Thierry Laugel, managing partner of the Paris-based financiers, tells Scrip about the virtues of its 'company creation model,' giving innovative ideas time to mature rather than rushing to the market.
Compass raises $132m in Series A as it moves from screening to the clinic, and start-up HotSpot Therapeutics comes out of stealth mode with a $45m Series A financing co-led by Atlas Venture and Sofinnova Partners.
- Antisense, Oligonucleotides